CO2024007518A2 - Formulaciones inyectables e inhalables - Google Patents
Formulaciones inyectables e inhalablesInfo
- Publication number
- CO2024007518A2 CO2024007518A2 CONC2024/0007518A CO2024007518A CO2024007518A2 CO 2024007518 A2 CO2024007518 A2 CO 2024007518A2 CO 2024007518 A CO2024007518 A CO 2024007518A CO 2024007518 A2 CO2024007518 A2 CO 2024007518A2
- Authority
- CO
- Colombia
- Prior art keywords
- dimethyltryptamine
- compound
- formulations
- optionally substituted
- aqueous pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110143066A TWI891942B (zh) | 2020-12-01 | 2021-11-18 | 氘化化合物 |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GBGB2119021.0A GB202119021D0 (en) | 2021-11-18 | 2021-12-24 | Injectable and inhalable formulations |
| US202217574424A | 2022-01-12 | 2022-01-12 | |
| EP2022055324 | 2022-03-02 | ||
| PCT/EP2022/082486 WO2023089132A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007518A2 true CO2024007518A2 (es) | 2024-07-29 |
Family
ID=84440034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007518A CO2024007518A2 (es) | 2021-11-18 | 2024-06-14 | Formulaciones inyectables e inhalables |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4433049A1 (ja) |
| JP (1) | JP2024540527A (ja) |
| KR (1) | KR20240110836A (ja) |
| AU (1) | AU2022393234A1 (ja) |
| CA (1) | CA3238583A1 (ja) |
| CL (1) | CL2024001452A1 (ja) |
| CO (1) | CO2024007518A2 (ja) |
| IL (1) | IL312859A (ja) |
| MX (1) | MX2024005955A (ja) |
| WO (1) | WO2023089132A1 (ja) |
| ZA (1) | ZA202403906B (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022553135A1 (en) | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666149A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20220071958A1 (en) * | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| PT3873883T (pt) | 2019-11-07 | 2023-03-24 | Small Pharma Ltd | Método de síntese |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| AU2021334933B2 (en) * | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
-
2022
- 2022-11-18 JP JP2024529536A patent/JP2024540527A/ja active Pending
- 2022-11-18 EP EP22818741.5A patent/EP4433049A1/en active Pending
- 2022-11-18 MX MX2024005955A patent/MX2024005955A/es unknown
- 2022-11-18 AU AU2022393234A patent/AU2022393234A1/en active Pending
- 2022-11-18 WO PCT/EP2022/082486 patent/WO2023089132A1/en not_active Ceased
- 2022-11-18 KR KR1020247020007A patent/KR20240110836A/ko active Pending
- 2022-11-18 IL IL312859A patent/IL312859A/en unknown
- 2022-11-18 CA CA3238583A patent/CA3238583A1/en active Pending
-
2024
- 2024-05-15 CL CL2024001452A patent/CL2024001452A1/es unknown
- 2024-05-20 ZA ZA2024/03906A patent/ZA202403906B/en unknown
- 2024-06-14 CO CONC2024/0007518A patent/CO2024007518A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202403906B (en) | 2025-08-27 |
| KR20240110836A (ko) | 2024-07-16 |
| EP4433049A1 (en) | 2024-09-25 |
| WO2023089132A1 (en) | 2023-05-25 |
| AU2022393234A1 (en) | 2024-06-06 |
| CL2024001452A1 (es) | 2024-09-27 |
| MX2024005955A (es) | 2024-06-11 |
| CA3238583A1 (en) | 2023-05-25 |
| IL312859A (en) | 2024-07-01 |
| JP2024540527A (ja) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eshraghi et al. | Enhancing autophagy in Alzheimer's disease through drug repositioning | |
| ES2708756T3 (es) | Materiales y métodos para mejorar la función pulmonar y para la prevención y/o el tratamiento de complicaciones pulmonares inducidas por radiación | |
| ES2897453T3 (es) | Aplicación de R-ketamina y sal de la misma como productos farmacéuticos | |
| ES2281439T3 (es) | Uso de anticonvulsionantes a base de aminoacidos para tratar el dolor. | |
| ES2381664T3 (es) | Combinaciones de antagonistas del receptor metabotrópico de glutamato y su uso en el tratamiento de trastornos adictivos | |
| ES2705698T3 (es) | Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib | |
| MX2021005969A (es) | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. | |
| ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
| AR077484A1 (es) | Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| JP2017533276A (ja) | 認知低下を処置するための方法 | |
| CO2024007518A2 (es) | Formulaciones inyectables e inhalables | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| ES2283406T3 (es) | Medicamentos intracorporeos para tratamiento fototerapeutico de alta energia de enfermedad. | |
| ES2984490T3 (es) | Composición que comprende nicotina para el tratamiento de hemorragias de la mucosa nasal o paranasal | |
| ES2276818T3 (es) | Agente que contiene n-clorotaurina, asi como su uso para el tratamiento de polipos de la mucosa. | |
| ES2952367T3 (es) | Conjugados terapéuticos basados en PAR-1 y usos de los mismos | |
| US20210015934A1 (en) | Method of Treating Parkinson's Disease | |
| US20180235940A1 (en) | Treatment and management of augmentation in restless legs syndrome | |
| Natalini et al. | Analgesic and cardiopulmonary effects of epidural romifidine and morphine combination in horses | |
| ES2309105T3 (es) | Utilizacion de s-(2,3-bispalmitoiloxi-(2rs)-propil)-cisteinil-gnndesnisfkek (malp-2). | |
| Yesmin et al. | Experimental models and behavioral parameters for evaluation of Parkinson disease | |
| Milne | Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy |